Drug intelligence / Profile preview

gadolinium cation (3+)

Development stage
Unknown
Lead developer
Bayer
Modality
Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Device-based Delivery → Drug Delivery Systems
Administration
Intravenous, Intraarticular, Intrathecal, Intra-arterial
01

Overview

Gadolinium cation (3+) is the trivalent form of the element gadolinium, represented as Gd3+. It is not used directly as a drug but serves as the active component in various gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI). In these agents, Gd3+ is tightly chelated by organic ligands to reduce toxicity and facilitate safe intravenous administration. The primary mechanism of action involves shortening T1 relaxation times in MRI, thereby enhancing image contrast in tissues with abnormal vascularity or blood-brain barrier disruption. Free Gd3+ ions are highly toxic due to their interference with calcium-dependent biological processes; thus, they are always administered in chelated forms such as gadoteric acid or other macrocyclic/linear complexes[1][8]. The development and manufacturing of these agents involve companies specializing in rare earth elements and pharmaceutical-grade chemicals.

Other names
Gd3+gadolinium(III) ion

Beyond the preview

Go deeper on gadolinium cation (3+).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gadolinium cation (3+).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call